Latham & Watkins represented the underwriters in the offering. POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development and global access to life-changing...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Inspire in the offering, while Shearman & Sterling advised Goldman Sachs, as sole book-running manager. Inspire Medical Systems, Inc. (NYSE: INSP) executd an...
You must be a Standard 1 Year member to access this content.
Harter Secrest & Emery LLP assisted Athenex, Inc., while the underwriter was represented by Latham & Watkins LLP. Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company...
You must be a Standard 1 Year member to access this content.
Latham & Watkins and Dentons represented atai in the transaction. atai Life Sciences (“atai”) announced the closing of a venture debt loan facility of up to...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Orchestra BioMed on the deal. Loeb & Loeb LLP served as legal counsel for HSAC2. Latham & Watkins LLP represented the capital...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Precision BioSciences, Inc. in the offering. Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the offering. Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented ApiJect Holdings in the transaction. ApiJect Holdings, Inc., the parent company of ApiJect Systems, Corp., a medical technology public-benefit corporation transforming...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological...
You must be a Standard 1 Year member to access this content.
DLA Piper represented Liquidia, while Latham & Watkins represented the underwriters in the offering. Liquidia Corporation, a biopharmaceutical company focused on the development and commercialization of...
You must be a Standard 1 Year member to access this content.
